Clinical Trial Update: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegylated interferon lambda to pegylated interferon alfa plus ribavirin for hepatitis C was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated Interferon Lambda (pegylated interferon lambda-1a)
• Pegylated interferon alfa (pegylated interferon alfa)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: WITHDRAWN